-
公开(公告)号：US20150283178A1
公开(公告)日：2015-10-08
申请号：US14680860
申请日：2015-04-07
申请人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
发明人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
IPC分类号： A61K35/17 , A61K31/519 , C07K16/30 , A61K31/53 , C07K14/725 , C07K16/28 , A61K31/436 , A61K39/395 , A61K45/06
CPC分类号： A61K35/17 , A61K31/436 , A61K31/519 , A61K31/53 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C12N5/0636 , C12N2501/599 , C12N2501/727 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
摘要翻译： 本发明提供了用于治疗与CD19表达相关的疾病的组合物和方法，例如通过如本文所述施用包含本文所述的CD19 CAR的重组T细胞与激酶抑制剂，例如本文所述的激酶抑制剂组合。 本发明还提供了本文所述的试剂盒和组合物。
-
公开(公告)号：US20180289694A1
公开(公告)日：2018-10-11
申请号：US15575703
申请日：2016-05-20
申请人： David Glass , Joan Mannick , Leon Murphy
发明人： David Glass , Joan Mannick , Leon Murphy
IPC分类号： A61K31/4745 , A61K31/436
摘要： The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
-
公开(公告)号：US20150140036A1
公开(公告)日：2015-05-21
申请号：US14540867
申请日：2014-11-13
申请人： Joan Mannick , David Glass , Leon Murphy
发明人： Joan Mannick , David Glass , Leon Murphy
CPC分类号： A61K39/39 , A61K31/436 , A61K31/4745 , A61K31/519 , A61K39/00 , A61K39/09 , A61K39/092 , A61K39/12 , A61K39/145 , A61K45/06 , A61K2039/55511 , C12N7/00 , C12N2760/16034 , G01N33/6854
摘要： The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
摘要翻译： 本发明部分地涉及通过部分mTOR抑制增强免疫应答的组合物和方法，例如用低剂量的免疫增强剂量的mTOR抑制剂如RAD001。
-
公开(公告)号：US10576076B2
公开(公告)日：2020-03-03
申请号：US15575703
申请日：2016-05-20
申请人： David Glass , Joan Mannick , Leon Murphy
发明人： David Glass , Joan Mannick , Leon Murphy
IPC分类号： A61K31/4745 , A61K31/436
摘要： The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
-
15.发明申请公开(公告)号：US20230052970A1
公开(公告)日：2023-02-16
申请号：US17937488
申请日：2022-10-03
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , David Glass , Thomas Huber , Julia Jascur , Carl H. June , Jihyun Lee , Joan Mannick , Michael C. Milone , Leon Murphy , Avery D. Posey , Huijuan Song , Yongqiang Wang , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： C07K16/28 , A61K35/17 , C07K16/30 , C07K14/705 , A61P35/02 , A61P35/00 , A61K48/00 , C07K14/725 , C12N15/86
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
-
公开(公告)号：US20220064316A1
公开(公告)日：2022-03-03
申请号：US17359211
申请日：2021-06-25
发明人： Jennifer Brogdon , Eugene Choi , Hilmar Erhard Ebersbach , David Jonathan Glass , Heather Huet , Carl H. June , Joan Mannick , Michael C. Milone , Leon Murphy , Gabriela Plesa , Celeste Richardson , Marco Ruella , Reshma Singh , Yongqiang Wang , Qilong Wu
IPC分类号： C07K16/28 , C07K14/725 , C07K19/00 , A61P35/00 , C07H21/04 , C07K14/715 , A61K39/395 , A61K38/17 , C12N5/00 , C12N15/63 , C07K14/705 , A61K35/12
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
公开(公告)号：US20190263914A1
公开(公告)日：2019-08-29
申请号：US16210480
申请日：2018-12-05
发明人： Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC分类号： C07K16/28 , A61K31/436 , C07K14/725 , C07K14/705 , C07K14/74 , C12N9/90 , A61K35/17 , C07K14/71 , C12N9/12
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：US11591404B2
公开(公告)日：2023-02-28
申请号：US16884867
申请日：2020-05-27
发明人： Jennifer Brogdon , Saar Gill , David Jonathan Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , C07K16/24 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
公开(公告)号：US10357514B2
公开(公告)日：2019-07-23
申请号：US14680860
申请日：2015-04-07
发明人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
IPC分类号： A61K35/17 , A61K39/395 , A61K31/519 , A61K45/06 , C07K14/725 , A61K31/436 , A61K31/53 , C12N5/0783 , C07K16/28 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
公开(公告)号：US20230026049A1
公开(公告)日：2023-01-26
申请号：US17661207
申请日：2022-04-28
发明人： Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K14/74 , C12N9/90 , C12N9/12 , C07K14/71 , A61K31/436 , A61K35/17
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.1 秒)